4 Lindenberg R. Significance of the tentorium in head injury from the blunt forces. *Clin Neurosurg* 1964;**12**:129–42.
5 Miller N, Newman N. *Walsh and Hoyt's clinical neuro-ophthamology,* 5th ed. Vol 1. Baltimore: Williams and Wilkins, 1998:1227–34.

CORRESPONDENCE

Toluene induced postural tremor

We read with interest the article by Miyagi *et al*[1] and comment on the medical treatment of toluene induced tremor. Microdialysis experiments in rats have shown that inhalation of toluene increases extracellular γ-aminobutyric acid (GABA) concentrations within the cerebellar cortex[2] which probably explains why GABA agonists including benzodiazepines (for example, clonazepam) are not very effective in toluene induced tremor and ataxia. Rat experiments also showed a 50% reduction in brain catecholaminergic neurons.[3] Degeneration of certain cerebellar pathways is probably responsible for the loss of this dopaminergic innervation.[4] Dopamine agonists could therefore be of potential interest in the treatment of toluene induced tremor. This hypothesis was explored in a recently described case,[5] which showed remarkable clinical and iconographic similarities with that described by Miyagi *et al*[1]: (*a*) long history of chronic toluene inhalation, (*b*) marked postural tremor, (*c*) progressive worsening of the symptoms despite abstinence from inhalant misuse, and (d) mild cerebral atrophy and marked low signal intensity in globus pallidi, thalami, red nuclei, and substantia nigrae on T2 weighted MRI. As our patient's tremor was progressive, medical treatment with a dopamine agonist was considered. One particular agent (amantadine) caught our attention because it had proved successful in the treatment of postural tremor and ataxias of heredodegenerative disorders in which the dentatorubro-olivary system is affected. In addition, there is evidence that catecholaminergic pathways are also involved in this type of ataxias, supported by low concentrations of these neurotransmitters in the CSF of patients with heredodegenerative ataxias.[6] In our patient, amantadine hydrochloride (100 mg twice daily) abolished postural tremor and ataxia completely over a 3 month period.

Subsequently, the treatment was discontinued, which resulted in relapse of the tremor and ataxia. He was rechallenged to amantadine, which progressively offered him the same clinical improvement as in the first 3 months. After 3 years the treatment was discontinued without any sign of relapse.

Although this finding needs confirmation, amantadine treatment could form a new approach in the medical treatment for toluene induced tremor and ataxia. Intractable cases would then justify a more aggressive approach such as ventrointermedius thalamotomy.

DIRK DELEU
Departments of Clinical Pharmacology and Neurology, College of Medicine, Sultan Qaboos University, PO Box 35, Al Khod, Muscat-123, Sultanate of Oman

YOLANDE HANSSENS
Drug Information Services, Hospital Pharmacy

Correspondence to: Dr Dirk Deleu, College of Medicine, PO Box 35, Sultan Qaboos University, Al-Khod, Muscat-123, Sultanate of Oman
email deleu@omantel.net.om

1 Miyagi Y, Shima F, Ishido K, Yasutakeet. Tremor induced by toluene misuse successfully treated by a Vim thalamotomy. *J Neurol Neurosurg Psychiatry* 1999;**66**:794–6.
2 Stengard K, Tham R, O'Connor WT, *et al*. Acute toluene exposure increases extracellular GABA in the cerebellum of rat: a microdialysis study. *Pharmacol Toxicol* 1993;**15**:327–34.
3 Bjornaes S, Naalsund LU. Biochemical changes in different brain areas after toluene inhalation. *Toxicology* 1988;**49**:367–74.
4 Campanella G, Filla A, De Falco F, *et al*. Friedreich's ataxia in the south of Italy: a clinical and biochemical survey of 23 patients. *Can J Neurol Sci* 1980;**7**:351–7.
5 Deleu D, Hanssens Y. Cerebellar dysfunction in chronic toluene abuse: beneficial response to amantadine hydrochloride. *J Toxicol Clin Toxicol* (in press).
6 Deutch AY, Elsworth JD, Roth RH, *et al*. 3-Acetylpyridine results in degeneration of the extrapyramidal and cerebellar motor systems: loss of dorsolateral striatal dopamine innervation. *Brain Res* 1990;**527**:96–102.

Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis

Nabbout *et al*[1] have attempted to identify the risk factors for the progression of subependymal nodules into giant cell astrocytomas (SEGAs) in tuberous sclerosis complex. In attempting to develop screening strategies that avoid iatrogenic morbidity, patient inconvenience, and excess cost, it is essential that the natural history of these lesions in the general population of patients with tuberous sclerosis complex be understood well.

We think that there are two problems with this study that should make the physician cautious about accepting the factors identified by Nabbout *et al* as a basis for a screening programme. The first is that this study was performed in a population that had been referred to a tertiary medical centre, and then had been further selected by virtue of having had at least 3 years tertiary centre follow up and needing two MR scans of the head. The prevalence of astrocytomas and risk factors, and hence the positive predictive value of any screening test in a general population of patients with tuberous sclerosis complex is likely to be different from those described in the highly selected group studied in this paper.

The second point is that the authors have made a potentially misleading decision to exclude more than half their study sample because they do not have lesions close to the foramen of Monroe. It is not certain that all SEGAs arise from lesions close to the foramen. They may arise in the fourth ventricle. Furthermore, the late presentation of many lesions in the lateral ventricles has, in the past, precluded accurate determination of their point of origin. The study selects 24 of 60 patients who had met their entry criteria but does not state how many of the excluded 36 patients had no subependymal nodules or nodules that were not "near the foramen of Monroe". Indeed no definition is given for what constitutes proximity to the foramen. The authors were apparently not blinded at the point when they selected which patients had lesions near to the foramen and therefore there is an obvious issue of potential selection bias.

The consequence of excluding these patients may have been that false significance is given to their results. The data they present are fragile. Consider, for example, the consequence of introducing from these 36 non-selected patients a hypothetical single case that had a family history of tuberous sclerosis complex and a subependymal nodule which enhanced with gadolinium. The effect would be to remove the stated statistical significance (using Fisher's exact tests) between the outcome and both of these explanatory variables.

Identifying the risk factors that can tell us which subependymal lesions will become invasive is important. As subependymal nodules and SEGAs seem to be histologically identical it is unlikely that pathologists will provide an answer. The study of Nabbout *et al* suggests some new hypotheses and reiterates some others. However, the definitive answer will not be provided by studies of selected samples but by follow up of a population based sample of patients with tuberous sclerosis complex. In the absence of such a study we would be cautious about implementing screening programmes based on what may be misleading criteria.

FINBAR J K O'CALLAGHAN
ANDREW LUX
JOHN OSBORNE
Bath Unit for Research in Paediatrics, Royal United Hospital, Bath BA1 3NG, United Kingdom

Correspondence to: Dr Finbar J K O'Callaghan, Bath Unit for Research in Paediatrics, Royal United Hospital, Bath BA1 3NG, United Kingdom

1 Nabout R, Santos M, Rolland Y, *et al*. Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis. *J Neurol Neurosurg Psychiatry* 1999;**66**:370–5.

Atypical form of amyotrophic lateral sclerosis: a new term to define a previously well known form of ALS

We read with interest the article by Sasaki *et al*[1] concerning the atypical form of amyotrophic lateral sclerosis (ALS). The pattern of muscular atrophy in these patients differed from that of typical ALS in that severe muscle involvement was confined to the upper limbs, predominantly the proximal portion and shoulder girdle, sparing the face and the legs until late in the disease's course or until the terminal stage.

Over the past few years, we have noticed a growing interest in the renaming of this clinical form of ALS, which has its origins and predomination in the proximal muscles and upper limbs and little or no effect of either a bulbar nature or in the lower limbs.

Thus Hu *et al*[2] coined the term flail arm syndrome, to describe a subgroup of patients affected by ALS that predominantly showed signs of lower motor neuron disease in the upper limbs, without significant functional involvement of other regions on clinical presentation. This subgroup of patients was clinically characterised by the display of progressive atrophy and weakness affecting the proximal muscles in the upper limb muscles in a more or less symmetric manner.

Recently, along these lines, Katz *et al*[3] described a series of patients affected by an adult onset motor neuron disorder restricted to the upper limbs, with severe proximal and varying degrees of distal involvement, calling it amyotrophic brachial diplegia syndrome.

Other terms used in the past to refer to this form of ALS have been dangling arm syndrome, suspended form, orangutan sign, dead arm sign, bibrachial palsy, rizomelic amyotrohy, and the idea of naming it a distinctive phenotype of a neurogenic